- Harpoon Therapeutics, Inc. stock is down over 55% since it released data on its most advanced early-stage program (HPN424 for metastatic castration-resistant prostrate cancer) in June 2020.
- The company has a total of four early-stage programs, the most important of which is HPN217, into which AbbVie can opt-in for $200 million.
- With an upgraded half-life versus its BiTE predecessors but significant competition from Amgen, Harpoon’s TriTAC platform and busted IPO stock merited a deeper dive.
- A full analysis follows in the paragraphs below.
For further details see:
Harpoon Therapeutics: A First Look